文献速递脊柱关节炎

银屑病关节炎中司库奇尤单抗与TNF抑制剂治疗留存与应答的比较

Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

基于北欧生物制剂注册研究,比较司库奇尤单抗与阿达木单抗等TNF抑制剂在银屑病关节炎中的治疗留存和应答。共纳入6143例患者8307个治疗疗程,按生物制剂治疗线分层分析。结果显示无论治疗线如何,司库奇尤单抗与阿达木单抗在治疗留存和DAPSA28缓解方面均无显著差异。

要点

  • 司库奇尤单抗与阿达木单抗的治疗停药风险比在各治疗线均无显著差异。
  • 6个月DAPSA28缓解的OR值在各治疗线均无统计学意义。
  • 既往TNFi因无效失败的患者中,换用另一种TNFi或司库奇尤单抗可能同等有效。

核心结论

  • 司库奇尤单抗与阿达木单抗在银屑病关节炎治疗留存和应答上无显著差异,无论治疗线如何。

研究设计与样本

  • 基于北欧国家生物制剂注册的观察性研究,纳入2015-2018年起始司库奇尤单抗或TNFi的银屑病关节炎患者。
  • 共识别6143例患者,贡献8307个治疗疗程,其中司库奇尤单抗1227个,阿达木单抗1367个。
  • 计算1年治疗留存率及停药风险比(HR),以及6个月DAPSA28缓解的比值比(OR),以阿达木单抗为参照并调整基线特征和合并症。
  • 所有分析按生物制剂治疗线(第一、第二、第三线及以上)分层。

主要发现

  • 司库奇尤单抗与阿达木单抗相比,调整后停药HR在第一、第二、第三线分别为0.98(95%CI 0.68,1.41)、0.94(0.70,1.26)、1.07(0.84,1.36)。
  • DAPSA28缓解的OR在第一、第二、第三线分别为0.62(95%CI 0.30,1.28)、0.85(0.41,1.78)、0.74(0.36,1.51)。
  • 在既往因无效停用TNFi的患者亚组中,结果相似。

关键数值与推荐

  • 治疗留存和应答无临床显著差异,HR和OR均无统计学意义。

临床怎么用

  • 在银屑病关节炎中,司库奇尤单抗与阿达木单抗等TNFi的疗效和留存相当,治疗选择可考虑患者个体情况。
  • 对于既往TNFi无效的患者,换用另一种TNFi或司库奇尤单抗可能同样有效。

局限性

  • 观察性注册研究,可能存在未测量混杂。
  • 司库奇尤单抗作为一线生物制剂使用较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare treatment retention and response to secukinumab vs adalimumab, including the other four TNF inhibitors (TNFi) as comparators, in PsA. METHODS: All patients with PsA starting secukinumab or a TNFi in 2015-2018 were identified in the biologic registers of the Nordic countries. Data on comorbidities were linked from national registers. One-year treatment retention and hazard ratios (HRs) for treatment discontinuation were calculated. The proportion achieving a 6 month 28-joint Disease Activity Index for Psoriatic Arthritis (DAPSA28) remission was determined together with odds ratios (ORs) for remission (logistic regression). Both HRs and ORs were calculated with adalimumab as the reference and adjusted for baseline characteristics and concurrent comorbidities. All analyses were stratified by the line of biologic treatment (first, second, third+). RESULTS: We identified 6143 patients contributing 8307 treatment courses (secukinumab, 1227; adalimumab, 1367). Secukinumab was rarely used as the first biologic, otherwise baseline characteristics were similar. No clinically significant differences in treatment retention or response rates were observed for secukinumab vs adalimumab. The adjusted HRs for discontinuation per the first, second and third line of treatment were 0.98 (95% CI 0.68, 1.41), 0.94 (0.70, 1.26) and 1.07 (0.84, 1.36), respectively. The ORs for DAPSA28 remission in the first, second and third line of treatment were 0.62 (95% CI 0.30, 1.28), 0.85 (0.41, 1.78) and 0.74 (0.36, 1.51), respectively. In the subset of patients previously failing a TNFi due to ineffectiveness, the results were similar. CONCLUSION: No significant differences in treatment retention or response were observed between secukinumab and adalimumab, regardless of the line of treatment. This suggests that even in patients who have failed a TNFi, choosing either another TNFi or secukinumab may be equally effective.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Lindström U, Glintborg B, Di Giuseppe D, et al. Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. Rheumatology (Oxford). 2021. PMID: 33367900. doi:10.1093/rheumatology/keaa825

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。